Company Filing History:
1 out of 15,543 
1 out of 5,468 
1 out of 340 
Years Active: 2019
Title: The Innovative Contributions of Dimitrios Monikis
Introduction
Dimitrios Monikis is a notable inventor based in Riverside, CA (US). He has made significant contributions to the field of receptor biology, particularly through his innovative research and patenting activities. His work focuses on the modulation of C5a receptor activity, which has implications for various therapeutic applications.
Latest Patents
Dimitrios Monikis holds a patent for the discovery of the first selective C5A receptor 2 (C5L2/C5AR2) ligands. This patent outlines a method for selectively modulating the activity of C5a receptor 2 (C5aR2). The method involves exposing the receptor to a compound that selectively modulates C5aR2 compared to C5a receptor 1 (C5aR1). Notably, the compounds used in this method include peptide P32 or P59. Additionally, the patent provides methods for recruiting β-arrestin 2 in a cell, modulating C5a-induced ERK1/2 activation in a macrophage, and selectively inhibiting the release of IL-6 from a macrophage.
Career Highlights
Throughout his career, Dimitrios Monikis has worked with prestigious institutions such as the University of California and the Texas A&M University System. His research has contributed to advancements in understanding receptor mechanisms and their potential therapeutic targets.
Collaborations
Dimitrios has collaborated with notable colleagues, including Christodoulos A Floudas and Trent Martin Woodruff. These collaborations have further enriched his research and expanded the impact of his work in the scientific community.
Conclusion
Dimitrios Monikis is a pioneering inventor whose work on C5a receptor modulation has opened new avenues for research and potential therapies. His contributions to the field are significant and continue to influence advancements in receptor biology.